LATEST ONCOPRESCRIBE UPDATES
Late Breaking Abstract – ASCO 2026: CEL MoDs Significantly Extend Progression-Free Survival in Relapsed and Refractory Multiple Myeloma
SUMMARY: Multiple Myeloma (MM) is a clonal disorder of plasma cells in the bone marrow and the American Cancer Society estimates that in the United States, 36,000 new …Late Breaking Abstract – ASCO 2026: BREAKWATER Cohort 3 Expands First-Line Targeted Therapy Options for BRAF V600E-Mutant Metastatic Colorectal Cancer
SUMMARY: Colorectal cancer (CRC) is the third most common cancer diagnosed in both men and women in the United States. The American Cancer Society estimates that approximately 158,850 new cases …Late Breaking Abstract – ASCO 2026: ctDNA-Guided Early Treatment Escalation Improves Outcomes in EGFR-Mutated Advanced NSCLC
SUMMARY: The American Cancer Society estimates that for 2026, about 229,410 new cases of lung cancer will be diagnosed and 124,990 patients will die of the disease. Lung …FDA Approves WELIREG® with KEYTRUDA® for Adjuvant Treatment of Renal Cell Carcinoma
SUMMARY: The FDA on June 12, 2026, approved Belzutifan (WELIREG®) in combination with Pembrolizumab (KEYTRUDA®) or Pembrolizumab and Berahyaluronidase alfa-pmph (KEYTRUDA QLEX®) for the adjuvant treatment …FDA Approves IBRANCE® with HER2 Targeted Therapy and Endocrine Therapy as Maintenance Treatment in HR-positive, HER2-positive Advanced Breast Cancer
SUMMARY: The FDA on June 24, 2026, approved IBRANCE® (Palbociclib) in combination with Trastuzumab, with or without Pertuzumab, and endocrine therapy for the maintenance treatment …Late Breaking Abstract – ASCO 2026: Ivonescimab Plus Chemotherapy Delivers Superior Overall Survival Benefit in Advanced Squamous NSCLC
SUMMARY: The American Cancer Society estimates that for 2026, about 229,410 new cases of lung cancer will be diagnosed and 124,990 patients will die of the disease. Lung cancer …Late Breaking Abstract – ASCO 2026: Evidence for Comprehensive PI3K/AKT/mTOR Pathway Inhibition in HR-Positive, HER2-Negative Advanced Breast Cancer
SUMMARY: Breast cancer is the most common cancer among women in the US and about 1 in 8 women (12%) will develop invasive breast cancer during …FDA Approves All-Oral Treatment for Newly Diagnosed Acute Myeloid Leukemia
SUMMARY: The FDA on May 13, 2026, approved an oral combination of Decitabine and Cedazuridine tablets (INQOVI®) with Venetoclax for the treatment of newly diagnosed …
NEW REGIMENS ADDED
VYLOY® with mFOLFOX 6 - for Gastric and GEJ cancer
VYLOY® (Zolbetuximab) with ELOXATIN® (Oxaliplatin), 5-FU and Leucovorin. Regimen for Gastric and GastroEsophageal Junction adenocarcinoma whose tumors are Claudin (CLDN) 18.2 positiveVYLOY® with CAPOX - for Gastric and GEJ cancer
VYLOY® (Zolbetuximab) with ELOXATIN® (Oxaliplatin) and XELODA® (Capecitabine). Regimen for Gastric and GastroEsophageal Junction adenocarcinoma whose tumors are Claudin (CLDN) 18.2 positiveENHERTU® - for Breast Cancer
Single Agent ENHERTU® (fam-trastuzumab deruxtecan-nxki) for Ultralow Metastatic Breast CancerOPDIVO® and YERVOY® with Limited Course Chemotherapy - for Non Small Cell Lung Cancer
OPDIVO® (Nivolumab) and YERVOY® (Ipilimumab) with 2 cycles of TAXOL® (Paclitaxel) and PARAPLATIN®(Carboplatin) - for advanced NSCLCJAYPIRCA® - for Mantle Cell Lymphoma
JAYPIRCA® (Pirtobrutinib) for Mantle Cell Lymphoma
Curbside Consultation
Bottom Ad
Advertisement
Subscribe
